Thrombin-binding substance and process for preparing the same

Abstract: Novel thrombin-binding substances (A) and (B) are disclosed. The thrombin-binding substances have the following characteristics: (a) molecular weight: Thrombin-binding substance (A): 90,000-92,000 under reduced conditions 55,000-58,000 under unreduced conditions Thrombin-binding substance (B): 98,000-105,000 under reduced conditions 60,000-65,000 under unreduced conditions (b) isoelectric point: Thrombin-binding substance (A): pH 6.0-6.8 Thrombin-binding substance (B): pH 5.8-6.5 (c) affinity: strong affinity to thrombin (d) activity: (1) capable of promoting the thrombin catalyzed activation of protein C (2) prolongs clotting time; and (e) stability: stable to denaturing agents (sodium dodecylsulfate and urea). The thrombin-binding substances are useful as a medicine for curing thrombosis.

Description: This invention relates to a novel thrombin-binding substance, and, more particularly, to a thrombin-binding substance useful as a medicine, especially a medicine for curing thrombosis, involving anticoagulation and fibrinolytic systems which control blood coagulation, and a process for the preparation of the thrombin-binding substance. A great deal of work have been done regarding the role that thrombin plays as a proteolytic enzyme in the control mechanism of blood coagulation and the mechanism of blood coagulation has been elucidated for the most part. According to a publication it was reported that thrombin activated Protein C which is said to act on the fibrinolytic and anticoagulant systems. The publication also reports that there is a certain substance in extracts of rabbit lung tissue which functions as a coenzyme for the activation mechanism. Such a substance was named thrombomodulin [N. L. Esmon et al, J. Biological Chemistry, 257 , (2), 859-864 (1982)]. N. Aoki, one of the present inventors, and others have reported human thrombomodulin separated from human placenta and having characteristics similar to the thrombomodulin reported by J. Biological Chemistry, with a molecular weight of about 71,000 under unreduced conditions [ Thromb. Res., 37 , 353-364 (1985)]. Furthermore, I. Maruyama et al reported that the comparison of activities of human thrombomodulin separated from human placenta with a molecular weight of about 71,000 (under unreduced conditions) and those of the above-mentioned rabbit thrombomodulin revealed that they had identical activities [ J. Clin. Invest., 75 , 987-991 (1985)]. It has also been reported by H. Ishii et al that human plasma and urine contain substances having the same activities as thrombomodulin and the molecular weights of such substances in plasma are 63,000 and 54,000 [ J. Clin. Invest., 76 , 2178-2181 (1985)]. The present inventors had discovered in human urine two types of thrombin-binding substances which are different from the above-mentioned substances and having smaller molecular weights, i.e., about 39,000 and 31,000 under unreduced conditions, and filed a patent application on these substances (Japanese Patent Laid-open No. 146898/1988). The inventors have continued further extensive studies in order to develop an advantageous process for the production, isolation, and purification of human thrombomodulin, and as a result separated from human urine two types of thrombin-binding substances [hereinafter defined as thrombin-binding substances (A) and (B)] which are different from above-mentioned previously discovered substances. The inventors confirmed that the two thrombin-binding substances are novel compounds. The present inventors conducted further studies in order to develop an industrially advantageous process for producing and isolating these thrombin-binding substances. As a result, the inventors discovered that the same thrombin-binding substances found in urine are present in a culture broth of cells derived from human tissues and that the target substances can be separated and collected from the culture broth using simple procedures. Such findings have led to the completion of the present invention. Accordingly, an object of the present invention is to provide thrombin-binding substances (A) and (B) having the following characteristics: (a) molecular weight: Thrombin-binding substance (A): 90,000-92,000 under reduced conditions 55,000-58,000 under unreduced conditions Thrombin-binding substance (B): 98,000-105,000 under reduced conditions 60,000-65,000 under unreduced conditions (b) isoelectric point: Thrombin-binding substance (A): pH 6.0-6.8 Thrombin-binding substance (B): pH 5.8-6.5 (c) affinity: strong affinity to thrombin (d) activity: (1) capable of promoting the thrombin catalyzed activation of protein C (2) prolongs clotting time; and (e) stability: stable to denaturing agents (sodium dodecylsulfate and urea). Another object of the present invention is to provide a process for preparing said thrombin-binding substances which comprises: treating human urine with calcium ion, and separating and purifying a thrombin-binding substance by immunoadsorption column chromatography using a monoclonal antibody, which is capable of recognizing structural changes in the thrombin-binding substance by calcium ion, and by a molecular weight fractionation method. Still another object of the present invention is to provide a process for preparing said thrombin-binding substances which comprises: culturing cells derived from human tissues, and separating and purifying the thrombin-binding substance from the culture broth. Other objects, features and advantages of the invention will hereinafter become more readily apparent from the following description. The thrombin-binding substances of the present invention is useful as a fibrinolytic accelerator or as an anticoagulant since they combine with thrombin and specifically activate protein C and prolong the blood clotting time. The thrombin-binding substances of this invention can be prepared, for example, by the following methods: Method (1) Treating human urine with calcium ion, and separating and purifying the thrombin-binding substances by immunoadsorption column chromatography using a monoclonal antibody which is capable of recognizing structural changes in the thrombin-binding substances caused by the calcium ion, followed by a molecular weight fractionation. Method (2) Culturing cells derived from human tissues and performing the same separation and purification procedures as Method (1) mentioned above. In the above first method, fresh human urine or a human urine concentrate is used. They may be pretreated by one or more methods selected from ion-exchange chromatography, gel filtration, affinity chromatography using a thrombin-bound carrier, and the like. When ion-exchange chromatography is used for the pretreatment, it is preferable that urine of which pH is adjusted to 8-12 is contacted with DEAE-Sephadex A-50 (trade name, product of Pharmacia AB), DEAE-TOYOPEARL 650C, 650M, or 650S (trade name, product of Toyo Soda Mfg. Co. Ltd.) or QAE-Sephadex A-50 (trade name, product of Pharmacia AB), to adsorb the target substances, and washed with a buffer solution containing a salt, e.g. sodium chloride, at a low concentration, followed by elution with the same buffer solution with a higher salt concentration. Gel filtration is carried out using Sephadex® G 150 (trade name, product of Pharmacia AB) or Ultrogel® AcA 34 (trade name, product of LKS Co.), as a carrier. Affinity column chromatography can be carried out using a thrombin-bound carrier in which thrombin is inactivated, for example, with diisopropylfluoro phosphate, and bound on an insoluble carrier, for example, agarose gel, sepharose gel, dextran gel, and polyvinyl gel. Treatment of urine with calcium ion is performed by adding a calcium compound such as calcium chloride, calcium and carbonate, calcium hydroxide, either immediately before immunoadsorption column chromatography or during the pretreatment. In general, the addition of these compounds in an amount to bring the calcium ion concentration to 2-10 mM causes thrombin-binding substances having a calcium-binding site to selectively combine with calcium and to change their structure. The monoclonal antibody capable of specifically recognizing such structural changes can be prepared, for example, by fusing mouse spleen cells, which have been immunized with the above-mentioned thrombin-binding substances extracted from human placentae and having a molecular weight of about 71,000, with mouse myeloma cells P3-Ag8-γ, selecting antibody producing hybridomas, then selecting hybridomas which do not immunologically react with the thrombin-binding substances in the presence of EDTA, i.e., hybridomas which produce an antibody which is capable of recognizing such structural changes, followed by conventionally known methods (Japanese Patent Laid-open No. 45398/1989). It is desirable to use as an immunoadsorbent a monoclonal antibody bound carrier in which a monoclonal antibody for the thrombin-binding substances is bound on an insoluble carrier such as dextran gel, agarose gel and, polyvinyl gel. Elution by immune adsorption column chromatography can be carried out using, for example, a buffer solution containing EDTA. High performance liquid chromatography using ion-exchange resin or electrophoresis can be used for the molecular weight fractionation. An anion-exchange resin such as TSK gel®, e.g. DEAE-5PW®, DEAE-2SW®, or DEAE-3SW®, (trade names, product of Toyo Soda Mfg. Co., Ltd.) and Mono Q HR5/5® (trade name, product of Pharmacia AB) is preferable as an ion-exchange resin for high performance liquid chromatography. Conventional methods, for example, the Laemmli's method using SDS-polyacrylamide gel Nature, 227 , 680-685 (1970)] can be used as a method for electrophoresis. Cells which can be used in the present invention may be any cells derived from human and are capable of producing the thrombin-binding substances of the present invention. Such cells include, for example, cells derived from kidneys, lungs, intestinum tenues, skins, and hearts, of human fetuses, and cells derived from kidneys, lungs, foreskins, placentae, and lymphatic corpuscles, of human adults. Culture of the cells can be performed according to the methods which are conventionally applied to the culture of animal cells, for example, according to the method described in Tissue Culture Methods and Applications (P. K. Kruse and M. K. Patterson, Academic Press, 1973). The Method (1) mentioned previously can be used for the separation and purification of the thrombin-binding substances from the culture broth. The thrombin-binding substances (A) and (B) of this invention have calcium binding sites and change their structure by the treatment with calcium ions. Tissue culture media generally used for animal cells contain calcium ions, and therefore structurally changed thrombin-binding substances are produced in such media. When a medium not containing calcium ion is used, the calcium ion treatment is required before the culture broth is subjected to immune adsorption column chromatography. The treatment can be carried out by the addition of a calcium compound such as calcium chloride, calcium carbonate and, calcium hydroxide, In general, the addition of these compounds in an amount to bring the calcium ion concentration to 2-10 mM causes thrombin-binding substances having a calcium-binding site to selectively combine with calcium and to change their structure. Thrombin-binding substances thus prepared have the following characteristics: (a) Molecular weight: Thrombin-binding substance (A): 90,000-92,000 under reduced conditions 55,000-58,000 under unreduced conditions Thrombin-binding substance (B): 98,000-105,000 under reduced conditions 60,000-65,000 under unreduced conditions Method of measurement: Molecular weights were measured in accordance with the Laemmli's method based on SDS-PAGE using 10% acrylamide-0.8% bisacrylamide. "Bio-Rad SDS-PAGE® standard for High Molecular Substances" (trade name: product of Nippon Bio-Rad Laboratories Inc.) was used as a standard protein. (b) Isoelectric point: Thrombin-binding substance (A): pH 6.0-6.8 Thrombin-binding substance (B): pH 5.8-6.5 Method of measurement: Isoelectric points were measured according to the isoelectric point electrophoresis using Pharmacia Phast System [Plate: IEF (3-9)]. (c) Amino acid compositions: Amino acid compositions were determined according to the method proposed by Spacksman et al [ Anal. Chem., 30, 1190 (1958)] using Beckman 6300E®-type Amino Acid Analyzer (trade name, manufactured by Beckman Inc.). The results are shown in Table 1. Table 1 includes, as comparative data, amino acid compositions of thrombin-binding substances reported in the following publications: (I) J. Biol. Chem. 259 , 12246 (1984) (II) International Publication No. WO 87/00050 (III) Japanese Patent Laid-open No. 6219/1989 (IV) Japanese Patent Laid-open No. 301791/1988 The comparative data in Table 1 were calculated based on the data disclosed in these publications according to the same standard. (d) Sugar composition: Sugar compositions of thrombin-binding substances (A) and (B) were measured using an automatic sugar analyzer. The results are shown in Table 2. Sugars Sugar composition (µg/A₂₈₀) (A) (B) Neutral sugars D-mannose 24.3 21.1 L-fucose 15.3 13.6 D-glucose 27.3 31.1 Amino sugars D-galactosamine 6.0 11.3 D-glucosamine 53.5 47.1 Sialic acid N-acetylneuraminic acid 32.4 41.4 Total 158.8 165.6 (e) Affinity: The thrombin-binding substances have strong affinity to thrombin. 100% of both substances (A) and (B) were absorbed in a chromatographic treatment using diisopropylphosphoro-thrombin-agarose [ J. Biological Chemistry, 245 , 3059-3065 (1970)]. (f) Activity: (1) The thrombin-binding substances bind thrombin to activate protein C. Method of measurement: 10 µl of either one of the substances of the present invention or human thrombomodulin extracted from plancentae (5 ng/ml) dissolved in a 0.02 M Tris-HCl buffer containing 0.15 M sodium chloride (pH 7.5, hereinafter referred to as TBS), 30 µl of a TBS solution (1µM) of human protein C, and 10 µl of TBS, 1% bovine serum albumin, and 5 mM calcium chloride were mixed. To this mixture 50 µl of a TBS solution of human thrombin (5U/ml) was added and reacted at 37°C for 30 minutes, followed by an addition of 100 µl of a TBS solution of human ATIII (50 µg/ml) and a further reaction at 37°C for 10 minutes. To the resulting reaction mixture, 200 µl of a TBS solution containing Boc-Leu-Ser-Thr-Arg-MCM substrate (200 µM) was added to effect a reaction at 37°C for 10 minutes. Thereafter, 600 µl of 20% acetic acid was added to terminate the reaction. The concentration of dissociated AMC was measured at an exciting light wavelength of 380 nm and an emitting light wavelength of 460 nm, whereby the concentration of activated protein C was determined. Results are shown in Table 3. Samples (5 ng/ml) Concentration of AMC (nmol/ml.min) Thrombin-binding substance (A) 13.8 Thrombin-binding substance (B) 13.6 Human thrombomodulin obtained from placentae 14.0 (2) Thrombin-binding substances prolong the blood clotting time. Method of measurement: 10 µl of a TBS solution of a sample (10 µg/ml) was added to 200 µl of a 10 mM calcium chloride-containing TBS solution (0.05 U/ml) of bovine thrombin (product of Mochida Pharmaceutical Co., Ltd.). After incubation at 37°C for 30 minutes, 200 µl of human fibrinogen was added to the solution and the clotting time was immediately measured using a fibrometer. The results are shown in Table 4. Sample (10 µg/ml) Clotting time (sec.) Thrombin-binding substance (A) 100 Thrombin-binding substance (B) 105 Human thrombomodulin obtained from placentae 120 Bovine serum albumin 78 (g) Stability: Thrombin-binding substances (A) and (B) are stable to denaturing agents (sodium dodecylsulfate and urea). Method of measurement: 45 µg of the substance was treated under the conditions shown in Table 5 at 37°C for 60 minutes. After the treatment, the substance was diluted 100-fold with TBS to measure the residual activity. The results are shown in Table 5. Conditions Residual activities Treatment by reduction with 1% mercaptoethanol 0 Denaturing treatment 1% SDS 100 8 M Urea 100 Since the thrombin-binding substances of this invention are high molecular weight substances with calcium-binding sites, they can be expected to exhibit more natural pharmaceutical effects than thrombin-binding substances with smaller molecular weight. In addition, such thrombin-binding substances can be industrially produced using abundantly available human urine or cells derived from human tissues as a raw material. Other features of the invention will become apparent in the course of the following description of the exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof. EXAMPLES Example 1 600 l of fresh urine was adjusted to pH 9.0 using 6 N aqueous sodium hydroxide and left at 4°C overnight. After removing produced precipitates, 8 l of QAE-Sephadex A-50, the pH of which had been adjusted to 9.0 in advance, was added and the mixture was stirred at 4°C for 2 hours. The resin was collected using a glass filter, washed with 10 l of 0.02 M Tris-HCl buffer (pH 7.6) containing 0.05 M sodium chloride, and eluted using 20 l of 0.02 M Tris-HCl buffer (pH 7.6) containing 2 M sodium chloride. To the eluate was added ambonium sulfate to an 80% saturation and the mixture was left at 4°C overnight. The precipitates thus produced were collected by centrifugation, dissolved in 10 l of 0.02 M Tris-HCl buffer (pH 7.6) containing 0.05 M sodium chloride, and dialyzed three times against 100 l of the same buffer. To the dialyzed solution was added calcium chloride to a concentration of 5 mM and the resultant solution was subjected to a diisopropylphosphoro-thrombin-agarose column. After washing with 20 l of 0.02 M Tris-HCl buffer (pH 7.6) containing 0.05 M sodium chloride and 5 mM calcium chloride, the column was eluted gradiently between 5 l of 0.02 M Tris-HCl buffer containing 0.05 M sodium chloride (minimum NaCl concentration) and 5 mM ethylenediaminetetraacetic acid and the same buffer containing 1 M sodium chloride (maximum NaCl concentration) and 5 mM ethylenediaminetetraacetic acid. The eluate was fractionated into 100 ml portions. The active fractions were collected and dialyzed three times against 100 l of the same buffer containing 0.05 M sodium chloride. The dialyzed solution thus obtained was subjected to a column packed with 500 ml of immunoadsorbent comprising a monoclonal antibody (TM-A91) and agarose (Japanese Patent Laid-open No. 45398/1989). After washing with 300 l of said buffer containing 1 M calcium chloride, the column was eluted with 5 l of the same buffer containing 3 M sodium thiocyanate and 5 mM ethylenediaminetetraacetic acid. The eluate was washed three times with 50 l of the same buffer containing 0.05 M sodium chloride, dialyzed against 100 l of deionized water, and freeze-dried to obtain 10 mg of powder. The powder was dissolved in 80 ml of 0.01 M Tris-HCl buffer containing 1% sodium dodecyl sulfate, 0.5% glycerol, and 0.01% bromophenol blue, and the solution was heated at 100°C for 5 minutes. After heating, SDS-PAGE was performed according to the Laemmeli's method [ Nature, 227 , 680-685 (1970)] using 10% acrylamide-0.8% bisacrylamide to separate active fractions. Each of two fractions thus obtained was washed with water, dipped into 0.02 M Tris-HCl buffer (pH 7.5) containing 1% sodium dodecyl sulfate, and left at 4°C overnight to elute the target substances. The eluate was condensed and freeze-dried to produce 6 mg of thrombin-binding substance (A) and 2 mg of thrombin-binding substance(B). Example 2 1 liter of fresh urine was dialyzed three times against 5 l of 0.02 M Tris-HCl buffer (pH 7.4) containing 0.05 M sodium chloride. To the dialyzed solution was added calcium chloride to a concentration of 5 mM. The dialyzed solution thus obtained was subjected to a column packed with 1 ml of immunoadsorbent of the same type as used in Example 1. After washing with 100 ml of said buffer containing 0.05 M sodium chloride, 5 mM calcium chloride, and 0.05% Tween 20, and then with 100 ml of the same buffer containing 1 M sodium chloride and 5 mM calcium chloride, the column was eluted using 100 ml of the same buffer containing 3 M sodium thiocyanate and 5 mM ethylenediaminetetraacetic acid. The eluate was dialyzed three times against 500 ml of the same buffer containing 0.05 M sodium chloride, and freeze-dried to obtain 5 µg of powder. The same SDS-PAGE as in Example 1 was performed to obtain 3 µg of thrombin-binding substance (A) and 1 µg of thrombin-binding substance (B). Example 3 1 ton of fresh human urine was purified with a column of immunoadsorbent comprising a monoclonal antibody (TM-A73) and QAE-Sephadex A-50, then with a diisopropylphosphoro-thrombin-agarose column, and condensed to a volume of 5 ml using Milipore Immersible CX-10. The condensate was subjected to an Ultrogel AcA 34 column (2.7 x 90 cm) and eluted with Tris-HCl buffer to fractionate into 2.4 ml portions. 5 mg of thrombin-binding substance (B) was obtained from the fractions 90-97 and 3 mg of thrombin-binding substance (A) was obtained from fractions 127-145. Example 4 2 x 10⁵ of kidney cells obtained from human adults were inoculated into a 75 cm² flat bottom container, to which 25 ml of MEM containing 10% of bovine fetus serum which was heat treated at 56°C for 30 minutes. The cells were cultured using a carbon dioxide incubator at 37°C under 5% carbon dioxide atmosphere until the cells grew to form a layer. After confirmation of the cell growth, the liquid was removed and cell surfaces were thoroughly washed with a phosphate buffer. The cells were further cultured in an MEM medium containing 20 mg/ml of proteose peptone for 7 days. Thrombin-binding substances contained in the supernatant were measured by the ELISA method using monoclonal antibodies A-59 and A-73 and the content was found to be 10 ng/ml. When foreskin cells of human adults were cultured in the same manner as above, the culture broth supernatant contained 40 ng/ml of thrombin-binding substances. Example 5 A 1 liter culture broth of kidney cells obtained from human adults and cultured in the same manner as in Example 4 was passed through a column packed with 1 ml of Sepharose (2 mg IgG/ml resin) to which monoclonal antibody A-73 was bonded. After washing with 20 ml of 0.02 M Tris-HCl buffer (pH 7.4) containing 1 M sodium chloride, the column was eluted with 5 ml of the same buffer containing 2 M sodium thiocyanate and 5 mM EDTA and the eluate was dialyzed against 0.02 M Tris-HCl buffer containing 0.1 M sodium chloride. The dialyzed solution was subjected to an Ultrogel AcA 34 column (1.7 x 90 cm) and eluted with 0.02 M Tris-HCl (pH 7.4) buffer containing 0.15 M sodium chloride at a rate of 0.1 ml/minute to fractionate into 2.4 ml portions. Fractions No. 90-95 (Fraction I) were collected together and confirmed to contain 4 µg of thrombin-binding substances by the ELISA method in the same manner as in Example 4. In the same way, fractions No. 125-135 (Fraction II) were found to contain 3 µg of thrombin-binding substances. Example 6 SDS-PAGE was performed according to the Laemmli's method ( Nature, 227 , 680-685) on Fractions I and II obtained in Example 5 and on the thrombin-binding substances (A) and (B) produced in Examples 1-3. The gel was transcripted onto a PVDF membrane according to the Matsudaira's method [ J. Biol. Chem., 262 (21) , 10035-10038]. The PVDF membrane was then reacted in TBS containing 0.1% bovine serum albumin at room temperature for 2 hours. After discharging the solution, the residue was washed thoroughly with a 0.05% Tween 20-TBS, reacted in a 0.05% Tween 20-TBS 50 mM which contained monoclonal antibody A-73 labeled with horseraddish peroxidase at room temperature for 1 hour, and washed thoroughly with a 0.05% Tween 20-TBS. The liquid was discharged, and the residue was washed thoroughly with a 0.05% Tween 20-TBS and put into 50 ml of an acetic acid buffer (pH 5.0) containing 5 mg of 3-amino-9-ethylcarbazole and 25 µl of 30% hydrogen peroxide to get colored. Fraction I had a color at the same site with thrombin-binding substance (B) derived from urine and Fraction II had a color at the same site with thrombin-binding substance (A) derived from urine. Example 7 Each 100 µg of thrombin-binding substances (A) and (B) was subjected to Edmon degradation using a gas phase sequencer, and PTH-amino acids obtained were analyzed using a PTH analyzer. As a result, no amino acid peak was detected, evidencing that N-terminals of the thrombin-binding substances (A) and (B) were protected.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, NL, SE A thrombin-binding substance having the following characteristics: (a) molecular weight: 90,000-92,000 under reduced conditions 55,000-58,000 under unreduced conditions (b) isoelectric point: pH 6.0-6.8 (c) affinity: has strong affinity to thrombin (d) activity: (1) capable of promoting the thrombin catalyzed activation of protein C (2) prolongs clotting time; and (e) stability: stable to denaturing agents (sodium dodecylsulfate and urea). A thrombin-binding substance having the following characteristics: (a) molecular weight: 98,000-105,000 under reduced conditions 60,000-65,000 under unreduced conditions (b) isoelectric point: pH 5.8-6.5 (c) affinity: strong affinity to thrombin (d) activity: (1) capable of promoting the thrombin catalyzed activation of protein C (2) prolongs clotting time; and (e) stability: stable to denaturing agents (sodium dodecylsulfate and urea). A process for preparing the thrombin-binding substance defined in Claim 1 comprising: treating human urine with calcium ion, and separating and purifying a thrombin-binding substance by immunoadsorption column chromatography using a monoclonal antibody, which is capable of recognizing structural changes in the thrombin-binding substance by calcium ion, and by a molecular weight fractionation method. A process for preparing the thrombin-binding substance defined in Claim 2 comprising: treating human urine with calcium ion, and separating and purifying a thrombin-binding substance by immunoadsorption column chromatography using a monoclonal antibody, which is capable of recognizing structural changes in the thrombin-binding substance by calcium ion, and by a molecular weight fractionation method. A process for preparing the thrombin-binding substance defined in Claim 1 comprising: culturing cells derived from human tissues, and separating and purifying the thrombin-binding substance from the culture broth. A process for preparing the thrombin-binding substance defined in Claim 2 comprising: culturing cells derived from human tissues, and separating and purifying the thrombin-binding substance from the culture broth. The process according to Claim 5 or 6, wherein said separation and purification of the thrombin-binding substance comprise subjecting said culture broth to immunoadsorption column chromatography using a monoclonal antibody, which is capable of recognizing structural changes in the thrombin-binding substance by calcium ion, and then to molecular weight fractionation. Claims for the following Contracting State : ES A process for preparing a thrombin-binding substance having the following characteristics: (a) molecular weight: 90,000-92,000 under reduced conditions 55,000-58,000 under unreduced conditions (b) isoelectric point: pH 6.0-6.8 (c) affinity: has strong affinity to thrombin (d) activity: (1) capable of promoting the thrombin catalyzed activation of protein C (2) prolongs clotting time; and (e) stability: stable to denaturing agents (sodium dodecylsulfate and urea), said process being characterized in that it comprises: treating human urine with calcium ion, and separating and purifying a thrombin-binding substance by immunoadsorption column chromatography using a monoclonal antibody, which is capable of recognizing structural changes in the thrombin-binding substance by calcium ion, and by a molecular weight fractionation method. A process for preparing a thrombin-binding substance having the following characteristics: (a) molecular weight: 98,000-105,000 under reduced conditions 60,000-65,000 under unreduced conditions (b) isoelectric point: pH 5.8-6.5 (c) affinity: strong affinity to thrombin (d) activity: (1) capable of promoting the thrombin catalyzed activation of protein C (2) prolongs clotting time; and (e) stability: stable to denaturing agents (sodium dodecylsulfate and urea), said process being characterized in that it comprises: treating human urine with calcium ion, and separating and purifying a thrombin-binding substance by immunoadsorption column chromatography using a monoclonal antibody, which is capable of recognizing structural changes in the thrombin-binding substance by calcium ion, and by a molecular weight fractionation method. A process for preparing the thrombin-binding substance defined in Claim 1 comprising: culturing cells derived from human tissues, and separating and purifying the thrombin-binding substance from the culture broth. A process for preparing the thrombin-binding substance defined in Claim 2 comprising: culturing cells derived from human tissues, and separating and purifying the thrombin-binding substance from the culture broth. The process according to Claim 3 or 4, wherein said separation and purification of the thrombin-binding substance comprise subjecting said culture broth to immunoadsorption column chromatography using a monoclonal antibody, which is capable of recognizing structural changes in the thrombin-binding substance by calcium ion, and then to molecular weight fractionation.

Inventors: AOKI NOBUO, KIMURA SHIGERU, SHIRATSUCHI MASAMI, AOKI, NOBUO, KIMURA, SHIGERU, SHIRATSUCHI, MASAMI
Applicants: KOWA CO, KOWA COMPANY, LTD.
Application year: 1989
Main classification: A61K35
IPC codes: C07K14, A61K38, C07K1, C12P21, A61P7, C12R1